奥氮平联合喹硫平治疗精神分裂症的疗效观察

Effects of Olanzapine combined with quetiapine in treatment of schizophrenic patients

目的:观察奥氮平联合喹硫平治疗精神分裂症的疗效。方法:选择76例精神分裂症患者为研究对象。根据随机数字表法将患者分为对照组和观察组各38例。对照组使用奥氮平片治疗,观察组采用奥氮平联合喹硫平治疗,比较两组治疗前后PANSS评分情况及临床疗效。结果:两组治疗前阳性症状、阴性症状、一般病理症状及PANSS总评分比较,差异无统计学意义(P>0.05);两组治疗后阳性症状、阴性症状、一般病理症状及PANSS总评分均较治疗前显著降低,且观察组明显低于对照组(P<0.05)。两组患者治疗前SCS-C、RSAS-C评分及肝脏脂肪含量比较,差异无统计学意义(P>0.05);两组患者治疗后均较治疗前SCS-C升高、RSAS-C降低、肝脏脂肪含量增加,且观察组SCS-C升高、RSAS-C降低较对照组明显(P<0.05),而肝脏脂肪含量增加两组间比较差异无统计学意义(P> 0.05);观察组总有效率(97.37%)明显高于对照组(84.21%),差异有统计学意义(P<0.05)。结论:奥氮平联合喹硫平治疗精神分裂症的疗效优于单纯奥氮平治疗。

Objective： To explore effects of Olanzapine combined with Quetiapine in treatment of schizophrenic patients. Methods： 76 schizophrenic patients were selected as the research subjects. These patients were divided into control group and observation group by random number table grouping method, 38 cases in each group. The control group was treated with Olanzapine tablets alone, while the observation group was treated with Olanzapine combined with Quetiapine. The PANSS scores and clinical effects were compared between the two groups before and after the treatment. Results： There were no significant differences in the scores of the positive symptoms, negative symptoms, general pathological symptoms as well as the PANSS scores between the two groups before the treatment （ P〉0.05）; however, after the treatment, these scores of the two groups decreased significantly than those before the treatment, and those of the observation group were significantly lower than those of the control group （ P〈0.05）. There were no significant differences in the SCS-C and RSAS-C scores and liver fat content between the two groups before the treatment （ P〉0.05; however, after the treatment, the SCS-C score increased, the RSAS-C decreased and the liver fat content increased of the two groups. The changes of the SCS-C and RSAS-C scores of the observation group were more obvious than those of the control group, but the difference in the liver fat content between the two groups was not significant （P〉0.05）. The efficiency （97.37%） of the observation group was significantly higher than that of the control group （84.21%）, and the difference was statistically significant （P〈0.05）. Conclusions： The efficacy of Olanzapine combined with Quetiapine in the treatment of the patients with schizophrenia is superior to single Olanzapine.